#3712 Simultaneous liver—kidney transplantation: a single-center experience in Croatia

Abstract Background and Aims Simultaneous liver and kidney transplantation (SLKT) has been established as the treatment of choice for patients with concurrent end-stage liver and end-stage kidney diseases. The objective of this study was to analyze the outcomes of SLKT in Croatia. Method Databases of the Eurotransplant and Clinical Hospital Merkur from December 2007 to July 2024 were retrospectively reviewed. Patient survival was analysed by the Kaplan Meier method, while multiple logistic regression was used to assess independent association of predictors (donor and recipient age at time of SLK, pretransplant dialysis vintage and liver disease diagnosis) with patient survival. Results From 2007–2024, a total of 34 SLKT were performed at our institution. There were 7 female patients and 27 male patients. The median age of the patients at the time of SLKT was 57.9 (interquartile range 51.2;64) years). The indications for liver transplantation were ethylic liver cirrhosis, hyperoxaluria type 1, polycystic liver disease, primary or secondary biliary cirrhosis, hepatitis B and C cirrhosis and criptogenic liver disease. The kidney transplantation indications were end-stage renal disease of various causes, glomerulonephritis, hyperoxaluria type 1, polycystic kidney disease, diabetic nephropathy and chronic kidney disease of unknown etiology The median follow-up duration for SLKT patients was 4.1 (1.4;10.5) years. The 1-year, 5 -year and 10-year overall patient survival rates were 75.5 %, 65.4 % and 45.3 %, respectively. In a multivariate analysis only higher donor age was associated with poorer patient survival (OR 1.073 [1.006–1.145] P = 0.0325), while other variables ( recipient age, liver disease and dialysis vintage) were not independently associated with overal patient survival. Conclusion Our results are in line with other major publications on SLKT patient survival. SLKT is good treatment option for selected patients with liver and end stage kidney disease.